



Date: February 8, 2024

To,
BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street,
Mumbai – 400 001
Scrip Code: 543434

To,
National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G
Bandra Kurla Complex
Bandra (E), Mumbai – 400 051
Scrip Symbol: SUPRIYA

Dear Sir/Madam,

Subject: Press Release- Unaudited Financial Results for the quarter and nine months ended December 31, 2023

The Board of Directors of the Company at their Meeting held on February 7, 2024 has inter alia, considered and approved the Unaudited Financial Results for the quarter and nine months ended December 31, 2023.

Please find attached the Press Release with regard to the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2023.

Kindly take the same on record and acknowledge the receipt.

Thanking you,

For Supriya Lifescience Limited

Shweta Singh
Company Secretary & Compliance Officer
Membership No.: A44973

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com



SUPRIYA LIFESCIENCE LTD.

Supriya Lifescience reports 213% jump in Net Profit in Q3FY24, EBITDA zooms 195%

Mumbai, February 8, 2024: The unaudited financial statements for the third quarter of FY24 have been released by Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic.

Key Consolidated Financial Highlights:

Particulars	Q3 FY24	Q3 FY23
Revenues (in Rs Cr)	140.07	105.14
Gross Profit (in Rs Cr)	85.45	53.79
EBITDA (in Rs Cr)	41.49	14.05
PAT (in RsCr)	29.79	9.52
PAT Margin	21.6%	9.1%
Quarterly EPS (in Rs)	3.76	1.18

Key Highlights for Q3 FY24:

In the third quarter of FY24, Supriya Lifescience Ltd. witnessed remarkable growth in its revenue, reporting a 33.2% year-over-year increase, reaching Rs. 140.07 crore compared to Rs. 105.14 crore in Q3 FY23.

Gross Profit for Q3 FY24 stood at Rs. 85.45 crore, with a growth of 59% compared to Rs. 53.79 crore in Q3 FY23.

EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore, with an EBITDA Margin of 29.6%, as opposed to an EBITDA of Rs. 14.05 crore in Q3 FY23 with an EBITDA margin of 13.4%. This marks a growth of 195.4% YoY.

The Profit After Tax (PAT) for Q3 FY24 more than tripled over the same quarter last year. PAT stood at Rs29.79 crore, up 213% YoY compared to Rs 9.52 crore in Q3 FY23.

The PAT Margin has gone up to 21.6% in Q3 FY24, compared to 9.1% in Q3 FY23.

The company's business in Asia picked up this quarter, contributing 42% to the net revenue, the same as from Europe. This led to a more balanced revenue distribution across regions.

The Analgesic and Anesthetic segment led the revenue growth and contributed to 49% of sales in Q3 FY24, compared to 21% in the corresponding quarter last year.

The company has reported significant growth over the nine months of the current quarter. For the first nine months of FY24, the company's profit has grown 59% to Rs 82.18 crore, as against 51.63 crore reported during the same period last year.

The company has recorded a total revenue of Rs 412.19 crore, 29% higher than last year. EBITDA margin expanded to 28.5% during the nine months in FY24 from 23.2% recorded in the corresponding period last year.

Mr. Satish Wagh, Chairman and Managing Director, Supriya Lifescience Ltd, commenting on the results, said, ""With a spectacular 33.2% year-over-year rise in sales to Rs. 140.07 crore, as well as significant increases in Gross Profit and EBITDA, these results demonstrate our dedication to long-term success. Notably, our triple-digit increase in Profit After Tax (PAT) to Rs. 29.79 crore, along with a strong PAT Margin of 21.6%, illustrates our emphasis on operational excellence. Furthermore, our strategic expansion into Asian and European markets, together with the growth of the Analgesic and Anaesthetic category, proves our capacity to embrace opportunities and react to changing market dynamics. Looking ahead, we are committed to advancing innovation and excellence, cementing Supriya Lifescience Ltd.'s position as a trusted leader in API production across several therapeutic categories."

.....
Disclaimer Statements in this "Document" describing the company's objectives, projections, estimates, expectations, plans or predictions, or industry conditions or events may be "forward-looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance, or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward-looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments or circumstances after the date hereof.

About Supriya Lifescience Ltd.:

Supriya Lifescience Ltd., a world-renowned producer of active pharmaceutical ingredients, was founded in 1987. Our cutting-edge facility has certifications from Health Canada, EUGMP, EDQM, USFDA, and NMPA. The company is headquartered in Mumbai, India, and our facility is located in Khed, District Ratnagiri. Our globally compliant facilities (EMA, US FDA, WHO, PMDA, TGA, KFDA, ANVISA) are supported by robust R&D, eight active CEPs, and fourteen active USDMFs. EHS requirements and ethical principles guide our core business. The

company's primary focus is to build intermediates and APIs for innovators and generic firms. We also exclusively collaborate with partners in the capacity of CMOs.

For More Details:

Krishna Raghunathan	Abhishek Chawande Mob: +91-9664516774
Supriya Lifescience Ltd	Dentsu Creative PR
e-mail: cfo@supriyalifescience.com	e-mail: abhishek.chawande@dentsu.com